-
LifeTech Capital Initiates Marina Biotech at Strong Speculative Buy (MRNA)
Friday, January 28, 2011 - 10:52am | 134LifeTech Capital is out with its report on Marina Biotech (NASDAQ: MRNA), after initiating MRNA at Strong Speculative Buy. In a note to clients, LifeTech Capital writes, "We believe that Marina Biotech represents one of the potential winners in the relatively new and fragmented RNAi space. In our...
-
Hapoalim Reiterates Hold on Eli Lilly (LLY)
Friday, January 28, 2011 - 10:46am | 115Hapoalim is out with its report today on Eli Lilly (NYSE: LLY), reiterating Hold after reporting in-line 2011 guidance. In a note to clients, Hapoalim writes, "The company forecasted 2011 continuing EPS in the range of $4.15 to $4.30, which contains our previous 2011 EPS estimate of $4.26. At $35....
-
Company News for January 28, 2011 - Corporate Summary
Friday, January 28, 2011 - 10:29am | 788• Microsoft (NASDAQ:MSFT) reported Q2 EPS of $0.77, above the Zacks Consensus Estimate of $0.55 per share. Revenues for the quarter were $19.95 billion, well above the Zacks Consensus Estimate of $16.073 billion • Amazon.com (NASDAQ:AMZN) reported Q4 EPS of $0.91, ahead of the Zacks Consensus...
-
Novartis to Buy Genoptix - Analyst Blog
Friday, January 28, 2011 - 9:40am | 524Novartis (NVS) recently announced that it has entered into a definitive agreement to acquire California based diagnostic laboratory, Genoptix Inc. (GXDX), for a cash consideration of $470 million. Genoptix is a specialist in providing personalized diagnostic services to community-based...
-
Pain Therapeutics Receives $5M Payment from King Pharmaceuticals
Friday, January 28, 2011 - 9:38am | 89Pain Therapeutics, Inc. (Nasdaq: PTIE) today announced that it had received a $5,000,000 milestone payment from King Pharmaceuticals, Inc. (NYSE: KG), its exclusive commercial partner for abuse-resistant prescription pain medications. Payment was made in connection with the acceptance by the U.S....
-
Novartis to Buy Genoptix - Analyst Blog
Friday, January 28, 2011 - 9:15am | 524Novartis (NVS) recently announced that it has entered into a definitive agreement to acquire California based diagnostic laboratory, Genoptix Inc. (GXDX), for a cash consideration of $470 million. Genoptix is a specialist in providing personalized diagnostic services to community-based...
-
Mylan Receives Approval for First-to-File Generic Sular
Friday, January 28, 2011 - 9:02am | 119Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Nisoldipine Extended-release Tablets, 8.5 mg, 17 mg, 25.5 mg and 34 mg. Mylan was the...
-
H.I.G. Capital Issues Statement in Response to Shareholder Letter to Matrixx Initiatives
Friday, January 28, 2011 - 8:40am | 160H.I.G. Capital, LLC today announced that it has reviewed the letter addressed to the Board of Directors of Matrixx Initiatives, Inc. (Nasdaq: MTXX) from BML Capital Management, LLC, dated January 25, 2011, regarding the pending tender offer for all of the outstanding shares of common stock of...
-
Busy Earnings Week Ahead - Earnings Preview
Friday, January 28, 2011 - 1:00am | 4956Earnings Preview 1/28/11 Next week the fourth quarter earnings season is in full swing. A total of 561 firms are due to report, including 106 S&P 500 firms. So far the earnings season seems to be going well. The firms reporting this week include several icons of U.S. business, including: Aflac...
-
Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib
Thursday, January 27, 2011 - 5:41pm | 109Sanofi-aventis (NYSE: SNY) and its subsidiary, BiPar Sciences, today announced that a randomized Phase III trial evaluating iniparib in patients with metastatic triple-negative breast cancer (mTNBC) did not meet the pre-specified criteria for significance for co-primary endpoints of overall...
-
BMY Misses by a Penny in Q4 - Analyst Blog
Thursday, January 27, 2011 - 2:31pm | 1017Bristol-Myers Squibb Company's (BMY) fourth quarter 2010 earnings (excluding special items worth $324 million) of 47 cents per share fell short of the Zacks Consensus Estimate by a penny. However, fourth quarter earnings remained flat from the year ago period. On a reported basis (including...
-
BMY Misses by a Penny in Q4 - Analyst Blog
Thursday, January 27, 2011 - 2:00pm | 1017Bristol-Myers Squibb Company's (BMY) fourth quarter 2010 earnings (excluding special items worth $324 million) of 47 cents per share fell short of the Zacks Consensus Estimate by a penny. However, fourth quarter earnings remained flat from the year ago period. On a reported basis (including...
-
Alcon's Winning Streak Continues - Analyst Blog
Thursday, January 27, 2011 - 1:01pm | 666Alcon Inc. (ACL) reported fourth quarter 2010 earnings of $1.74 per share, beating the Zacks Consensus Estimate of $1.70 and 8.1% ahead of the year-ago figure. The fiscal year also saw the company beating the Zacks Consensus Estimate by 4 cents. Earnings in fiscal year 2010 came in at $7.71 per...
-
Jefferies Comments on Eli Lilly's FY 2010 Earnings (LLY)
Thursday, January 27, 2011 - 12:50pm | 109Jefferies is out with its report today on Eli Lilly (NYSE: LLY), commenting on LLY's FY 2010 earnings. In a note to clients, Jefferies writes, "Net sales: $23.08bn (+6%CER) vs. JEF: $22.9bn and Cons. $22.9bn revenue beat expectations by 1%. 2010 results are marginally better than consensus...
-
Alcon's Winning Streak Continues - Analyst Blog
Thursday, January 27, 2011 - 12:30pm | 666Alcon Inc. (ACL) reported fourth quarter 2010 earnings of $1.74 per share, beating the Zacks Consensus Estimate of $1.70 and 8.1% ahead of the year-ago figure. The fiscal year also saw the company beating the Zacks Consensus Estimate by 4 cents. Earnings in fiscal year 2010 came in at $7.71 per...